HC Wainwright Predicts Valneva's Q3 Earnings (NASDAQ:VALN)

Key Points

• HC Wainwright has issued a Q3 2025 earnings estimate for Valneva, predicting earnings per share (EPS) of ($0.30) and maintaining a "Buy" rating with a $18.00 price target.
• Valneva reported a net revenue of $54.84 million for the last quarter, exceeding analyst expectations of $46.28 million, while the company experienced a negative net margin of 33.87%.
• Institutional investors currently hold 11.39% of Valneva's stock, reflecting recent activity from hedge funds that have modified their positions significantly.

Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) - HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Valneva in a report issued on Tuesday, August 19th. HC Wainwright analyst B. Folkes expects that the company will post earnings per share of ($0.30) for the quarter. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Valneva's current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva's Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $1.73 EPS, FY2028 earnings at $1.68 EPS and FY2029 earnings at $1.98 EPS.

Separately, Guggenheim dropped their price target on Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $16.00.

Valneva Trading Up 4.0%

Shares of VALN traded up $0.45 during midday trading on Thursday, hitting $11.64. The stock had a trading volume of 48,007 shares, compared to its average volume of 90,346. Valneva has a 1 year low of $3.62 and a 1 year high of $12.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. The stock's 50 day moving average is $7.41 and its 200 day moving average is $6.97. The firm has a market cap of $990.45 million, a PE ratio of -11.88 and a beta of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.11. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%.The business had revenue of $54.84 million during the quarter, compared to analyst estimates of $46.28 million.

Hedge Funds Weigh In On Valneva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its position in Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after purchasing an additional 30,859 shares during the period. GAMMA Investing LLC purchased a new stake in Valneva in the 1st quarter worth $94,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Valneva during the 2nd quarter worth about $8,240,000. Finally, Marex Group plc purchased a new position in Valneva in the 2nd quarter valued at $64,000. Hedge funds and other institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.